All In Biotech

Drug Trial Radar · NCT07282743

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of GL0034 Among Type II Diabetes Mellitus Subjects Who Are Obese or Overweight With Weight-related Comorbidities

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

285

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Apr 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.

Conditions

  • Type II Diabetes Mellitus

Interventions

  • GL0034 Dose Level 1Drug

    Dose 1, once a week

  • GL0034 Dose Level 2Drug

    Dose 2, once a week

  • GL0034 Dose Level 3Drug

    Dose 3, once a week

  • GL0034 Dose Level 4Drug

    Dose 4, once a week

  • GL0034 Dose Level 5Drug

    Dose 5, once a week

  • GL0034 Dose Level 6Drug

    Dose 6, once a week

  • PlaceboOther

    Placebo, once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participantsTime frame: Week 36

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Lynn Institute of the Ozarks

    Little Rock, Arkansas · Recruiting

  • Family First Medical Research Center

    Hialeah Gardens, Florida · Recruiting

  • Alliance for Multispecialty Research (AMR Clinical) - Wichita East

    Lakeland, Florida · Recruiting

  • CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis)

    Lakeland, Florida · Recruiting

  • GTL Medical & Research Group

    Miami, Florida · Recruiting

  • Florida Institute for Clinical Research LLC

    Orlando, Florida · Recruiting

  • AMR Clinical, El Dorado

    El Dorado, Kansas · Recruiting

  • AMR Clinical - Newton

    Newton, Kansas · Recruiting

  • Lynn Health Science Institute - Oklahoma City

    Oklahoma City, Oklahoma · Recruiting

  • Endolife Specialty Hospitals Pvt. Ltd.

    Guntur, Andhra Pradesh, India · Recruiting

  • Life Care Hospital and Research Centre

    Bangalore, Karnataka, India · Recruiting

  • Government Medical College

    Kozhikode, Kerala, India · Recruiting

  • Jothydevs Diabetes Research Centre

    Trivandrum, Kerala, India · Recruiting

  • Nirmal Hospital Private Limited

    Kolhāpur, Maharashtra, India · Recruiting

  • Topiwala National Medical College & BYL Nair Hospital

    Mumbai, Maharashtra, India · Recruiting

  • Seth G. S. medical college and KEM hospital

    Mumbai, Maharashtra, India · Recruiting

  • BSES Municipal General Hospital

    Mumbai, Maharashtra, India · Recruiting

  • LMMF's Deenanath Mangeshkar Hospital and Research Center

    Pune, Maharashtra, India · Recruiting

  • Lady Hardinge Medical College and S.S.K. Hospital

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • All India Institute of Medical Sciences

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • Madras Diabetes Research Foundation (MDRF)

    Chennai, Tamil Nadu, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.